Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Other Targets lists biosimilar antibodies whose targets fall outside the main groups or have few products. Examples include omalizumab and ligelizumab, which bind immunoglobulin E (IgE), and bimagrumab, which blocks activin type II receptors. Lirilumab targets killer-cell immunoglobulin-like receptors (KIRs) on natural killer cells. The group also includes antibodies to allergens, Wnt pathway receptors, proteases, transporters and intracellular proteins such as histones. Several fusion proteins and peptide conjugates are listed here as well, including the long-acting granulocyte colony-stimulating factor (G-CSF) analogs balugrastim and eflapegrastim.
Synonyms: SAND-26
Begelomab (SAND-26) is a murine IgG2b monoclonal antibody specifically targeting DPP-4/CD26. This antibody is utilized in research focused on severe refractory idiopathic inflammatory myopathy, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for this condition.
Synonyms: UCB6114
Ginisortamab (UCB6114) is a fully human IgG4P monoclonal antibody targeting Gremlin-1. It demonstrates potent inhibitory activity with mean IC50 values of 8.2 nM and 9 nM against human and mouse Gremlin-1, respectively. By antagonizing Gremlin-1, Ginisortamab effectively disrupts the BMP signaling pathways, which are crucial in various biological processes including tissue growth and repair. This antibody holds significant potential for use in research focused on gastrointestinal (GI) tumors, providing a valuable tool for elucidating the role of Gremlin-1 in cancer pathogenesis and therapy.
Anti-SLAMF7 / CS1 (PDL241) is a humanized monoclonal antibody specifically targeting CD319. This antibody is recognized for its potential as a therapeutic agent in the treatment of rheumatoid arthritis, leveraging its ability to modulate immune responses associated with the disease.
Verekitug is a human IgG1 κ monoclonal antibody targeting CRLF2. For optimal experimental control, it is recommended to use Human IgG1 kappa Isotype Control.
Synonyms: AMG-203; Anti-Human CSF2 Recombinant Antibody
Namilumab (AMG203) is a human IgG1 monoclonal antibody designed to bind with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF), effectively neutralizing its activity. This antibody is primarily utilized in research focused on understanding and treating rheumatoid arthritis, providing a valuable tool for investigating the role of GM-CSF in inflammatory processes.
GFB-024 is a recombinant humanized monoclonal antibody specifically designed to target the CB1 receptor, also known as CNR1. This antibody binds with high specificity and affinity, making it an essential tool for the study of CB1 receptor functions in various physiological and pathological processes. GFB-024 is ideal for applications in both basic research and therapeutic development related to the endocannabinoid system.
Derlotuximab is a chimeric antibody of the scFv-Fc (huIgG1) type, produced in Chinese Hamster Ovary (CHO) cells, and specifically targets Histone H1. This antibody has a predicted molecular weight of 145.1 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.
Birinkibart is a human monoclonal antibody of the IgG4κ subtype, specifically targeting the CSF2RB receptor. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This specificity and configuration make Birinkibart suitable for detailed studies on CSF2RB-related pathways and potential therapeutic applications.
Synonyms: CSL311
Trabikibart (CSL311) is a βc (CSF2RB)-specific, fully human monoclonal antibody engineered to target a unique epitope on the cytokine-binding site of the human βc receptor. Exhibiting a picomolar binding affinity, this antibody effectively binds to the receptor, demonstrating robust specificity. Trabikibart acts as a potent inhibitor of the combined biological activities of IL-3, GM-CSF, and IL-5, particularly impacting the survival of eosinophils. This characteristic positions Trabikibart as a valuable tool for investigating the mechanisms underlying chronic inflammatory diseases and exploring potential therapeutic interventions.
Synonyms: CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab); Nadunolimab
Nidanilimab (CAN04) is a fully humanized monoclonal antibody targeting IL1RAP, characterized by a high affinity with a dissociation constant (Kd) of 1.10 pM. This antibody effectively inhibits signaling pathways mediated by IL1α and IL1β, thereby enhancing immune system responses against tumor cells. Nidanilimab is primarily utilized in research focused on non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), offering significant potential for elucidating disease mechanisms and therapeutic interventions in these cancers.
The Anti-oxLDL Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target oxidized low-density lipoprotein (oxLDL). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is ideal for research applications focusing on the role of oxLDL in atherosclerosis and other related cardiovascular diseases.
Imeroprubart is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets FCGRT. For experimental control purposes, the recommended isotype control is Human IgG1 lambda2.
Synonyms: INT-001
Idactamab (INT-001) is an IgG1-κ monoclonal antibody demonstrating significant in vivo activity against a range of hematological malignancies. This antibody serves as a precursor for the synthesis of MEDI7247, a highly potent and specific antibody-drug conjugate (ADC) that targets ASCT2 (SLC1A5), offering therapeutic potential in oncology research.
Igovomab is a monoclonal antibody specifically designed for imaging applications in ovarian cancer research. This antibody targets antigens associated with ovarian cancer, facilitating the detailed study of disease pathology and aiding in the development of targeted therapies. Igovomab is utilized primarily in diagnostic research settings to improve the visualization and characterization of ovarian cancer tissues.
Synonyms: IMMU-MN3
Lemalesomab (IMMU-MN3) is a monoclonal antibody derived from mouse IgG1, specifically designed as a Fab' fragment targeting NCA-90. This antibody is utilized primarily in the study of inflammation, infectious lesions, and for the imaging of infections in research settings. Its specificity for NCA-90 makes it a valuable tool for detailed investigations into cellular processes associated with immune responses and microbial infection.
Synonyms: NI-0501
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody designed for the noncompetitive inhibition of interferon gamma (IFN-γ). It exhibits high binding affinity, with a dissociation constant (Kd) of 1.4 pM, to both free IFN-γ and IFN-γ that is bound to its receptor. This antibody is particularly useful in the study of hemophagocytic lymphohistiocytosis (HLH), providing a critical tool for research into the pathophysiology and potential therapeutic interventions for this condition.
Ebdarokimab (AK101) is a humanized IgG1-κ monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody is engineered for high specificity and affinity in targeting its designated antigens, ensuring effective application in therapeutic research.
Imzokitug is a humanized IgG1κ monoclonal antibody specifically targeting CKR-L1. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.
Synonyms: DISC-0974
The Anti-RGMC/HFE2 Antibody (DISC-0974) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting RGMC/HFE2. This antibody is composed of a human IgG1 heavy chain and a kappa light chain, with a predicted molecular weight of 145.66 kDa. For isotype control purposes, reference should be made to the Human IgG1 kappa Isotype Control. This antibody is suitable for a range of research applications, focusing on the study of RGMC/HFE2 function and expression.
Synonyms: MERS-3A1; MERS Antibody-3A1
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody, engineered with high binding affinity and produced in CHO cells. This antibody effectively blocks the interaction between the MERS-CoV spike protein and the DPP4 receptor, thereby inhibiting the virus's entry into host cells. It is an essential tool for research focused on the molecular mechanisms of MERS-CoV infection and potential therapeutic interventions.
The Anti-GAD65 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the GAD65 enzyme. This antibody features a human IgG1 heavy chain and a human lambda light chain, with a predicted molecular weight of 146.48 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is essential for research focused on the enzymatic function and regulation of GAD65, particularly in studies related to its role in neurological and autoimmune disorders.
Synonyms: SPECIFID
Detumomab is a mouse-derived monoclonal antibody specifically designed to target human B-cell lymphoma. This antibody is particularly useful in the study of various cancers, including non-Hodgkin's lymphoma (NHL), providing essential insights into disease mechanisms and potential therapeutic targets.
